[go: up one dir, main page]

WO2007053194A3 - Modulation of cell barrier dysfunction - Google Patents

Modulation of cell barrier dysfunction Download PDF

Info

Publication number
WO2007053194A3
WO2007053194A3 PCT/US2006/021604 US2006021604W WO2007053194A3 WO 2007053194 A3 WO2007053194 A3 WO 2007053194A3 US 2006021604 W US2006021604 W US 2006021604W WO 2007053194 A3 WO2007053194 A3 WO 2007053194A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
cell barrier
pseudomonas
mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/021604
Other languages
French (fr)
Other versions
WO2007053194A2 (en
Inventor
John C Alverdy
Jonathan Moss
Mark W Lingen
Patrick A Singleton
Joe G N Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/007892 external-priority patent/WO2006096626A2/en
Priority to US11/914,984 priority Critical patent/US20080194611A1/en
Priority to AU2006309292A priority patent/AU2006309292A1/en
Priority to EP06844131A priority patent/EP1901742A2/en
Priority to JP2008514938A priority patent/JP2008542395A/en
Priority to CA002609985A priority patent/CA2609985A1/en
Application filed by University of Chicago filed Critical University of Chicago
Publication of WO2007053194A2 publication Critical patent/WO2007053194A2/en
Publication of WO2007053194A3 publication Critical patent/WO2007053194A3/en
Anticipated expiration legal-status Critical
Priority to US13/483,932 priority patent/US20120316190A1/en
Priority to US14/061,331 priority patent/US20140142133A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides prophylactic and therapeutic methods for administering a μ-opioid receptor antagonist to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders. The diseases or disorders may amenable to the methods include inflammation, such as acute lung injury, atherosclerosis, gut-derived sepsis, a burn injury, neonatal necrotizing enterocolitis, severe neutropenia, toxic colitis, inflammatory bowel disease, enteropathy, transplant rejection, pouchitis, pig belly (pig-bel), Pseudomonas-mediated ophthalmologic infection, Pseudomonas-mediated otologic infection and Pseudomonas-mediated cutaneous infection. More generally, epithelial cell barrier disorders are contemplated as amenable to the prophylactic and therapeutic methods.. The diseases and disorders may be induced by microbial pathogens, including bacterial pathogens such as Pseudomonαs aeruginosa. The invention further provides prophylactic and therapeutic methods for inhibiting the expression of bacterial PA-I lectin/adhesin and for inhibiting bacterial MvfR activity levels. Also provided is a method of using a μ-opioid receptor antagonist in the manufacture of a medicament for use in the methods described herein.
PCT/US2006/021604 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction Ceased WO2007053194A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US11/914,984 US20080194611A1 (en) 2005-06-03 2006-05-06 Modulation of Cell Barrier Dysfunction
AU2006309292A AU2006309292A1 (en) 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction
EP06844131A EP1901742A2 (en) 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction
JP2008514938A JP2008542395A (en) 2005-06-03 2006-06-05 Regulation of cell barrier dysfunction
CA002609985A CA2609985A1 (en) 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction
US13/483,932 US20120316190A1 (en) 2005-06-03 2012-05-30 Modulation of Cell Barrier Dysfunction
US14/061,331 US20140142133A1 (en) 2005-06-03 2013-10-23 Modulation of cell barrier dysfunction

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US68756805P 2005-06-03 2005-06-03
US60/687,568 2005-06-03
US73100905P 2005-10-28 2005-10-28
US60/731,009 2005-10-28
US76085106P 2006-01-20 2006-01-20
US60/760,851 2006-01-20
USPCT/US2006/07892 2006-03-07
PCT/US2006/007892 WO2006096626A2 (en) 2005-03-07 2006-03-07 Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/007892 Continuation-In-Part WO2006096626A2 (en) 2005-03-07 2006-03-07 Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/914,984 A-371-Of-International US20080194611A1 (en) 2005-06-03 2006-05-06 Modulation of Cell Barrier Dysfunction
US13/483,932 Continuation US20120316190A1 (en) 2005-06-03 2012-05-30 Modulation of Cell Barrier Dysfunction

Publications (2)

Publication Number Publication Date
WO2007053194A2 WO2007053194A2 (en) 2007-05-10
WO2007053194A3 true WO2007053194A3 (en) 2007-08-09

Family

ID=38006351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/021604 Ceased WO2007053194A2 (en) 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction

Country Status (3)

Country Link
EP (1) EP1901742A2 (en)
CA (1) CA2609985A1 (en)
WO (1) WO2007053194A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314442B2 (en) 2014-03-25 2016-04-19 Leading BioSciences, Inc. Compositions for the treatment of autodigestion
US9504736B2 (en) 2010-09-23 2016-11-29 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
US9526723B2 (en) 2008-03-21 2016-12-27 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615646B2 (en) 2003-04-08 2022-07-27 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
JP5241484B2 (en) 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ Use of opioid antagonists to attenuate endothelial cell proliferation and endothelial cell migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
US7879870B2 (en) * 2006-04-19 2011-02-01 Smith Jill P Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
TWI489984B (en) 2006-08-04 2015-07-01 Wyeth Corp Formulations for parenteral delivery of compounds and uses thereof
JP5461386B2 (en) 2007-03-29 2014-04-02 プロジェニックス ファーマシューティカルズ，インコーポレーテッド Peripheral opioid receptor antagonists and uses thereof
SI2139890T1 (en) 2007-03-29 2014-12-31 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
MX351611B (en) 2007-03-29 2017-10-20 Wyeth Llc Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof.
KR101173509B1 (en) * 2007-10-05 2012-08-14 도레이 카부시키가이샤 Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient
JP5358587B2 (en) 2008-02-06 2013-12-04 プロジェニックス・ファーマシューティカルス・インコーポレイテッド Production and use of (R), (R) -2,2'-bis-methylnaltrexone
EP2306829B1 (en) 2008-07-01 2017-01-04 University of Chicago Particles containing a peripheral opioid receptor antagonist
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
CN117940554A (en) * 2022-06-30 2024-04-26 上海羽冠生物技术有限公司 Live bacterial strains of the genus Pseudomonas
CN119613494B (en) * 2025-02-12 2025-05-27 吉林农业大学 Antioxidant peptide derived from chanterelle fruiting body, antioxidant peptide detection reagent and application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
US20020173466A1 (en) * 1999-03-03 2002-11-21 Crain Stanley M. Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
WO2006132963A2 (en) * 2005-06-03 2006-12-14 The University Of Chicago Modulation of microbial pathogen-host cell interactions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20020173466A1 (en) * 1999-03-03 2002-11-21 Crain Stanley M. Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
WO2006132963A2 (en) * 2005-06-03 2006-12-14 The University Of Chicago Modulation of microbial pathogen-host cell interactions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZAGON I S ET AL: "OPIOID ANTAGONISTS INHIBIT THE GROWTH OF METASTATIC MURINE NEURO BLASTOMA", CANCER LETTERS, vol. 21, no. 1, 1983, pages 89 - 94, XP009083862, ISSN: 0304-3835 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526723B2 (en) 2008-03-21 2016-12-27 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US9504736B2 (en) 2010-09-23 2016-11-29 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
US10137100B2 (en) 2010-09-23 2018-11-27 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
US10772861B2 (en) 2010-09-23 2020-09-15 Leading Biosciences, LLC Administration of serine protease inhibitors to the stomach
US11439611B2 (en) 2010-09-23 2022-09-13 Leading BioSciences, Inc. Administration of serine protease inhibitors to the stomach
US9314442B2 (en) 2014-03-25 2016-04-19 Leading BioSciences, Inc. Compositions for the treatment of autodigestion
US9775821B2 (en) 2014-03-25 2017-10-03 Leading BioSciences, Inc. Compositions for the treatment of autodigestion
US11123317B2 (en) 2014-03-25 2021-09-21 Leading BioSciences, Inc. Compositions for the treatment of autodigestion

Also Published As

Publication number Publication date
CA2609985A1 (en) 2007-05-10
WO2007053194A2 (en) 2007-05-10
EP1901742A2 (en) 2008-03-26

Similar Documents

Publication Publication Date Title
WO2007053194A3 (en) Modulation of cell barrier dysfunction
MY161095A (en) Indole compound and pharmaceutical use thereof
WO2012149549A3 (en) Bacillus bacteria for use in treating and preventing infection in aquatic animals
WO2006132963A3 (en) Modulation of microbial pathogen-host cell interactions
EA201291441A1 (en) PROBIOTIC STRAINS FOR APPLICATION IN IMPROVING THE CONDITION OF THE INTESTINAL NERVOUS SYSTEM
WO2009143150A3 (en) Intestinal alkaline phosphatase modulators and uses thereof
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
WO2009109654A3 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40
EA201171270A1 (en) APPLICATION OF NIFURATEL IN THE TREATMENT OF INFECTIONS CAUSED BY ATOPOBIUM
WO2008036761A8 (en) Anti-microbial defensin-related peptides and methods of use
WO2008071961A8 (en) 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents
WO2007101264A3 (en) Method for treating endothelial and epithelial cell disorders by administering high molecular weight peg-like compounds
WO2010125196A3 (en) Bacteriophages specific to pak and cha strains of pseudomonas aeruginosa and their applications
PH12013500401A1 (en) Quinoxaline compound
WO2009114878A3 (en) Methods and compositions for genetic and retinal disease
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
WO2009068682A3 (en) Phenyl-oxetanyl-derivatives
WO2007108004A3 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
IL218467A0 (en) Picrorhiza kurroa extract for prevention elimination and treatment of infection diseases
WO2005118613A3 (en) Antibacterial amide macrocycles
WO2011061554A3 (en) Pharmaceutical composition for the treatment of bladder disorders
RU2011146815A (en) METHOD FOR PRODUCING A DRUG FOR ACTIVATION OF NON-SPECIFIC RESISTANCE, PREVENTION AND THERAPY OF AGRICULTURAL ANIMAL DISEASES
EP3520794A3 (en) Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
Atif et al. Comparative analysis of the antibacterial, antifungal, antiproliferative and cyclic response element (CRE) induced expression of downstream luc gene activities of Monopterus albus and Channa straitus extracts
CN102552885A (en) Piles and anus internal epithelium and rectum mucous epithelium cell anti-inflammation celltrex made of marine organisms

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006309292

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2609985

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008514938

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006844131

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11914984

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06844131

Country of ref document: EP

Kind code of ref document: A2